Feb 10, 2017 at 16:28 | Source: CNBC-TV18
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
Jan 12, 2017 at 08:21 | Source:
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Jan 09, 2017 at 14:06 | Source:
Portuguese drug regulator Infarmed issued observations on January 3 after it detected non-conformities in good manufacturing practices related to the granulation and primary packaging of tablets in batches of drugs related to paracetamol and metformin supplied to Mylan, Bluepharma and Sandoz.
Feb 22, 2016 at 21:16 | Source: PTI
As many as 277,267 bottles of Candesartan Cilexetil tablets manufactured by Mylan Laboratories are being recalled by Sandoz Inc, for whom they were made, in an ongoing recall due to "failed impurities/degradation specifications; 9 month stability time point," the report said.
Nov 04, 2015 at 12:23 | Source: CNBC-TV18
Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.
Oct 28, 2015 at 18:04 | Source: Reuters
The warning, issued to Novartis's generic drugs unit Sandoz on Oct. 22, came after FDA officials inspected its Turbhe and Kalwa sites in western India in August 2014.
Jul 30, 2015 at 13:10 | Source:
Kotak has a buy rating on Cipla with a target price of Rs 730 per share. Expecting launch of other two strengths (USD 600 million) in days to follow , the brokerage says Cipla will receive mark-up and profit share.
Dec 23, 2014 at 20:21 | Source: PTI
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.
Nov 07, 2014 at 10:04 | Source:
Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.
Nov 07, 2014 at 09:41 | Source: CNBC-TV18
Surajit Pal, pharma analyst, Prabhudas Lilladher, expects Teva, Mylan, Sandoz and Dr Reddys Laboratories to benefit from this loss.
Messages on Sandoz »


New Member


Sun Pharma  

sun pharma, mylan face price fixing charges in us. suit also filed against sandoz and mylan for colluding to hike price of another respiratory is falling because of this news

12.12 PM Mar 21st


New Member



and timelines show each company raising their prices by almost exactly the same amount within months of attending the meetings. wockhardt instituted price increases on its clobetasol product on the opening day of that meeting. then novartis s generic drug unit, sandoz ag, raised its own clobetasol prices about

3.55 PM Dec 16th 2016


New Member


Laurus Labs  

disclosure in this Draft Red Herring Prospectus in this context. .No Company Revenues (2015) (USD Bn) 1 Teva Pharmaceutical Industries 9.5 2 Sandoz 9.2 3 Mylan 8.17 4 Fresenius Kabi 5.9 5 Hospira (Now a part of Pfizer) 4.7 operators suvenlife ksk energy santha biotech medchal 6 Sun Pharmaceutical Industries

10.30 AM Dec 6th 2016


New Member



the global market for biosimilars is characterized by companies such as sandoz pharma, hospira, inc., actavis, , wockhardt ltd., biocon ltd. biosimilars for the pharmaceutical products such as insulin, human growth hormone, and blood products are considered as the high-interest market

12.47 PM Nov 4th 2016


Silver Member


Novartis India  

again? In this light one interesting observation in the case of buyback of Clariant Chemicals (from the same stable of erstwhile Sandoz): the company bought back at 950 around one year back and the share is no where close to that price even after a year, infact it had gone to 585 levels since

2.14 PM Sep 16th 2016


Gold Member


Parabolic Drugs  

, Mexican and Chinese authorities and USFDA is in the pipeline. The company had signed long term contracts with Ranbaxy, Sun Pharma, Sandoz, Lupin, Midas (Germany), Pfizer (USA), Meiji(Japan), Summit Pharma (Japan), Alkem, Shinogi and Merck but due to deadlock situation in terms of funds availability

12.18 PM Sep 5th 2016


New Member

0 Follower


sandoz,celltrion & Samsung bioepis...

3.42 PM Aug 31st 2016


Platinum Member


Novartis India  

Sandoz, the generic arm of Swiss drug maker Novartis, has decided to shut its facility for development of generic drugs in India Facility employed 157 people, who have been given notice till February

9.54 PM Jan 19th 2013


Platinum Member


Aurobindo Pharm  

today one of our zydus r n d mr.S B Roy given speech regarding zydus cadila growth and he wil left company within 3 to 4 days but he admire growth of aurobindo, sun, teva, novartis, mylan and sandoz.

10.19 PM Dec 25th 2012


Platinum Member



, the company said. The oral contraceptive market in the US is valued at around $5 billion and growing at around 8-10 per cent annually and is dominated by few companies like Teva, Watson, Sandoz and Bayer. Shares of Lupin were trading at Rs 618.45 on the BSE in late afternoon trade, up 1.62 per cent from its

5.21 PM Dec 19th 2012

Follow us on
Available On